PC
LGND icon

Pier Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Pier Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-64,094
Closed -$4.47M – 115
2020
Q2 		$4.47M Buy
+64,094
New +$4.06M 0.72% 85

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Pier Capital's LGND Position: Q3 2020 in Review

Pier Capital sold out of Ligand Pharmaceuticals (LGND) in Q3 2020, closing a stake of 64,094 shares — an estimated $4.47M sold.

Pier Capital first reported a position in LGND in Q2 2020 and held it in 1 quarter. The position peaked at $4.47M in Q2 2020. 252 funds tracked by Wall St. Rank hold LGND as of Q3 2020.

  • Pier Capital reported no remaining Ligand Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Pier Capital sold 64,094 Ligand Pharmaceuticals shares in Q3 2020, an estimated $4.47M.
  • Pier Capital first reported a position in Ligand Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Pier Capital's Ligand Pharmaceuticals position peaked at $4.47M in Q2 2020.
  • 252 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2020.

Based on Pier Capital's 13F filing for Q3 2020, filed 13 Nov 2020.